{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:22:59Z","timestamp":1794604979164,"version":"4.9.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal Plus: Cardiology Research and Practice"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ahjo.2026.100940","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:16:32Z","timestamp":1791357392000},"page":"100940","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Dynamic change in soluble suppressor of tumorigenicity 2 (sST2) during acute decompensated heart failure with a reduced ejection fraction, and its mortality implications"],"prefix":"10.1016","volume":"71","author":[{"given":"Brian","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Dowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Langley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paraic","family":"Cliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Whiting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Ganapathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony D.","family":"Dimarco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Barbagallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason N.","family":"Dungu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry Oluwasefunmi","family":"Savage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahjo.2026.100940_bb0005","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0014-5793(89)81679-5","article-title":"A putative protein of a growth specific cDNA from BALB\/C-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor","volume":"258","author":"Tominaga","year":"1989","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ahjo.2026.100940_bb0010","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/j.1460-2075.1994.tb06367.x","article-title":"Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor","volume":"13","author":"Bergers","year":"1994","journal-title":"EMBO J."},{"key":"10.1016\/j.ahjo.2026.100940_bb0015","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nri.2016.95","article-title":"Interleukin-33 in health and disease","volume":"16","author":"Liew","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ahjo.2026.100940_bb0020","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nrd2660","article-title":"The IL-33\/ST2 pathway: therapeutic target and novel biomarker","volume":"7","author":"Kakkar","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ahjo.2026.100940_bb0025","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.cyto.2008.03.008","article-title":"The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33","volume":"42","author":"Palmer","year":"2008","journal-title":"Cytokine"},{"key":"10.1016\/j.ahjo.2026.100940_bb0030","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1161\/01.CIR.0000038705.69871.D9","article-title":"Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction","volume":"106","author":"Weinberg","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ahjo.2026.100940_bb0035","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1161\/01.CIR.0000127958.21003.5A","article-title":"Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction","volume":"109","author":"Shimpo","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ahjo.2026.100940_bb0040","article-title":"2013 ACCF\/AHA guideline for the management of heart failure","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ahjo.2026.100940_bb0045","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines and the heart failure Society of Amer","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ahjo.2026.100940_bb0050","doi-asserted-by":"crossref","first-page":"1B","DOI":"10.1016\/j.amjcard.2015.01.033","article-title":"The international ST2 consensus panel: introduction","volume":"115","author":"Bayes-Genis","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ahjo.2026.100940_bb0055","doi-asserted-by":"crossref","first-page":"26B","DOI":"10.1016\/j.amjcard.2015.01.037","article-title":"ST2 and prognosis in acutely decompensated heart failure: the international ST2 consensus panel","volume":"115","author":"Januzzi","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ahjo.2026.100940_bb0060","doi-asserted-by":"crossref","first-page":"70B","DOI":"10.1016\/j.amjcard.2015.01.044","article-title":"ST2 testing for chronic heart failure therapy monitoring: the international ST2 consensus panel","volume":"115","author":"Januzzi","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ahjo.2026.100940_bb0065","series-title":"Circulating sST 2 and catestatin levels in patients with acute worsening of heart failure: a report from the CATSTAT-HF study","first-page":"2818","author":"Borovac","year":"2020"},{"key":"10.1016\/j.ahjo.2026.100940_bb0070","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jacc.2007.05.014","article-title":"Measurement of the interleukin family member ST2 in patients with acute dyspnea. Results from the PRIDE (pro-brain natriuretic peptide investigation of dyspnea in the emergency department) study","volume":"50","author":"Januzzi","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ahjo.2026.100940_bb0075","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jchf.2016.12.016","article-title":"Meta-analysis of soluble suppression of tumorigenicity-2 and prognosis in acute heart failure","volume":"5","author":"Aimo","year":"2017","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.ahjo.2026.100940_bb0080","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/j.jacc.2019.08.1039","article-title":"Clinical and prognostic significance of sST2 in heart failure: JACC review topic of the week","volume":"74","author":"Aimo","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ahjo.2026.100940_bb0085","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.cardfail.2008.06.415","article-title":"Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure","volume":"14","author":"Boisot","year":"2008","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.ahjo.2026.100940_bb0090","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000338800","article-title":"Serial monitoring of soluble interleukin family member ST2 in patients with acutely decompensated heart failure","volume":"122","author":"Manzano-Fern\u00e1ndez","year":"2012","journal-title":"Cardiology"},{"key":"10.1016\/j.ahjo.2026.100940_bb0095","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ahjo.2026.100940_bb0100","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.cardfail.2013.11.003","article-title":"Heart failure therapy-induced early ST2 changes may offer long-term therapy guidance","volume":"19","author":"Breidthardt","year":"2013","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.ahjo.2026.100940_bb0105","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1001\/jama.293.5.572","article-title":"Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis","volume":"293","author":"Fonarow","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ahjo.2026.100940_bb0110","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/eurheartj\/ehs337","article-title":"Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies","volume":"34","author":"Pocock","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ahjo.2026.100940_bb0115","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0895-4356(96)00236-3","article-title":"A simulation study of the number of events per variable in logistic regression analysis","volume":"49","author":"Peduzzi","year":"1996","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.ahjo.2026.100940_bb0120","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ahjo.2026.100940_bb0125","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S0002-9149(03)00741-0","article-title":"Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure","volume":"92","author":"Wu","year":"2003","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ahjo.2026.100940_bb0130","first-page":"1","article-title":"Natriuretic peptides in clinical practice","volume":"21","author":"\u00c7avu\u015fo\u011flu","year":"2019","journal-title":"Anatol. J. Cardiol."},{"key":"10.1016\/j.ahjo.2026.100940_bb0135","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/CIRCRESAHA.118.312706","article-title":"Established and emerging roles of biomarkers in heart failure","volume":"123","author":"Ibrahim","year":"2018","journal-title":"Circ. Res."},{"key":"10.1016\/j.ahjo.2026.100940_bb0140","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/ejhf.2346","article-title":"Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC)","volume":"23","author":"Meijers","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ahjo.2026.100940_bb0145","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.jacc.2017.09.026","article-title":"Prognostic value of serial ST2 measurements in patients with acute heart failure","volume":"70","author":"Vark","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ahjo.2026.100940_bb0150","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/heartjnl-2017-312183","article-title":"Routes to diagnosis of heart failure: observational study using linked data in England","volume":"104","author":"Bottle","year":"2018","journal-title":"Heart"},{"key":"10.1016\/j.ahjo.2026.100940_bb0155","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cardfail.2023.10.024","article-title":"HERMES: effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation","volume":"30","author":"Petrie","year":"2024","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.ahjo.2026.100940_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.cardfail.2005.04.006","article-title":"NT-ProBNP reduction percentage during admission for acutely decompensated heart failure predicts long-term cardiovascular mortality","volume":"11","author":"Bay\u00e9s-Gen\u00eds","year":"2005","journal-title":"J. Card. Fail."}],"container-title":["American Heart Journal Plus: Cardiology Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666602226002296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666602226002296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:01:13Z","timestamp":1794603673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666602226002296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":32,"alternative-id":["S2666602226002296"],"URL":"https:\/\/doi.org\/10.1016\/j.ahjo.2026.100940","relation":{},"ISSN":["2666-6022"],"issn-type":[{"value":"2666-6022","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dynamic change in soluble suppressor of tumorigenicity 2 (sST2) during acute decompensated heart failure with a reduced ejection fraction, and its mortality implications","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal Plus: Cardiology Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahjo.2026.100940","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100940"}}